



Attention, la Figure originelle contient 3 panels : A, B et C. Nous vous demandons de commenter seulement les panels A et B représentés ici.

FIGURE 4 Treatment of endothelium with ruxolitinib or fedratinib prevents TNF-α mediated cell velocity reduction at venous shear rate. A. Experimental schematic for endotheliazed devices and approach to evaluate effects on endothelial activation. HUVEC were cultured under flow for 3 days at 15 dynes/cm^2. Endothelialized devices were then treated with ± 10 ng/mL TNF-α and/or ± 0.4 μM ruxolitinib or 1 μM fedratinib for 4 hours. Whole blood from donors was collected in sodium citrated and labeled with calcein. Whole blood was then perfused over endothelial cells for 15 minutes at 1 dynes/cm^2. Image created in BioRender.com B. Cell velocity of calcein+ cells obtained from control blood donors (n = 7 donors with n = 3 to 7 replicates per conditions.

All data ± SE of means. p values from one-way repeated measure ANOVA with Holm–Sidak's multiple comparisons test. * $p < .05$, ** $p < .01$, *** $p < .001$, **** $p < .0001$.